Next, we studied whether silencing of STAP1 affected sensitivity for inhibitors of pre-BCR (ibrutinib) and mTOR signaling (rapamycin), and the ALL spearhead drug prednisolone. Here, MTOR is linked to acute lymphoblastic leukemia.